Search tips
Search criteria 


Logo of jcinvestThe Journal of Clinical InvestigationCurrent IssueArchiveSubscriptionAbout the Journal
J Clin Invest. 1998 April 1; 101(7): 1320–1325.
PMCID: PMC508709

Correction of renal tubular acidosis in carbonic anhydrase II-deficient mice with gene therapy.


Carbonic anhydrase II (CAII) deficiency in humans is associated with a syndrome of renal tubular acidosis, osteopetrosis, and cerebral calcification. A strain of mice of CAII deficiency due to a point mutation also manifests renal tubular acidosis. We report here that retrograde injection of cationic liposome complexed with a CAII chimeric gene, using a cytomegalovirus (CMV) promoter/enhancer as an expression cassette to drive human CAII cDNA, into the renal pelvis of CAII-deficient mice results in expression of CAII in the kidney. The levels of both the CAII gene and its corresponding mRNA were highest by day 3 after treatment, diminishing thereafter, but remaining detectable by 1 mo. After gene therapy, CAII-deficient mice restored the ability to acidify urine after oral administration of ammonium chloride. The ability to acidify urine was maintained at 3 wk after gene therapy, and was eventually lost by 6 wk. Immunohistochemistry studies using anti-CAII antibodies showed that CAII was expressed in tubular cells of the outer medulla and corticomedullary junction. The gene therapy was not associated with nephrotoxicity as assessed by blood urea nitrogen levels and renal histology. To our knowledge, this is the first successful gene therapy of a genetic renal disease. Our results demonstrate the potential of gene therapy as a novel treatment for hereditary renal tubular defects.

Full Text

The Full Text of this article is available as a PDF (305K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Tashian RE. Genetics of the mammalian carbonic anhydrases. Adv Genet. 1992;30:321–356. [PubMed]
  • Lönnerholm G, Ridderstråle Y. Intracellular distribution of carbonic anhydrase in the rat kidney. Kidney Int. 1980 Feb;17(2):162–174. [PubMed]
  • Tashian RE. The carbonic anhydrases: widening perspectives on their evolution, expression and function. Bioessays. 1989 Jun;10(6):186–192. [PubMed]
  • Sly WS, Hewett-Emmett D, Whyte MP, Yu YS, Tashian RE. Carbonic anhydrase II deficiency identified as the primary defect in the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification. Proc Natl Acad Sci U S A. 1983 May;80(9):2752–2756. [PubMed]
  • Lewis SE, Erickson RP, Barnett LB, Venta PJ, Tashian RE. N-ethyl-N-nitrosourea-induced null mutation at the mouse Car-2 locus: an animal model for human carbonic anhydrase II deficiency syndrome. Proc Natl Acad Sci U S A. 1988 Mar;85(6):1962–1966. [PubMed]
  • Brechue WF, Kinne-Saffran E, Kinne RK, Maren TH. Localization and activity of renal carbonic anhydrase (CA) in CA-II deficient mice. Biochim Biophys Acta. 1991 Jul 22;1066(2):201–207. [PubMed]
  • Curtis PJ. Cloning of mouse carbonic anhydrase mRNA and its induction in mouse erythroleukemic cells. J Biol Chem. 1983 Apr 10;258(7):4459–4463. [PubMed]
  • Lai LW, Moeckel GW, Lien YH. Kidney-targeted liposome-mediated gene transfer in mice. Gene Ther. 1997 May;4(5):426–431. [PubMed]
  • Lien YH, Lai LW. Liposome-mediated gene transfer into the tubules. Exp Nephrol. 1997 Mar-Apr;5(2):132–136. [PubMed]
  • Lien YH, Lai LW. Gene therapy for renal diseases. Kidney Int Suppl. 1997 Oct;61:S85–S88. [PubMed]
  • Felgner PL, Gadek TR, Holm M, Roman R, Chan HW, Wenz M, Northrop JP, Ringold GM, Danielsen M. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci U S A. 1987 Nov;84(21):7413–7417. [PubMed]
  • Zhu N, Liggitt D, Liu Y, Debs R. Systemic gene expression after intravenous DNA delivery into adult mice. Science. 1993 Jul 9;261(5118):209–211. [PubMed]
  • Stewart MJ, Plautz GE, Del Buono L, Yang ZY, Xu L, Gao X, Huang L, Nabel EG, Nabel GJ. Gene transfer in vivo with DNA-liposome complexes: safety and acute toxicity in mice. Hum Gene Ther. 1992 Jun;3(3):267–275. [PubMed]
  • Nabel GJ, Nabel EG, Yang ZY, Fox BA, Plautz GE, Gao X, Huang L, Shu S, Gordon D, Chang AE. Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. Proc Natl Acad Sci U S A. 1993 Dec 1;90(23):11307–11311. [PubMed]
  • Caplen NJ, Alton EW, Middleton PG, Dorin JR, Stevenson BJ, Gao X, Durham SR, Jeffery PK, Hodson ME, Coutelle C, et al. Liposome-mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Nat Med. 1995 Jan;1(1):39–46. [PubMed]
  • Aliño SF, Bobadilla M, Crespo J, Lejarreta M. Human alpha 1-antitrypsin gene transfer to in vivo mouse hepatocytes. Hum Gene Ther. 1996 Mar 1;7(4):531–536. [PubMed]
  • Wheeler CJ, Felgner PL, Tsai YJ, Marshall J, Sukhu L, Doh SG, Hartikka J, Nietupski J, Manthorpe M, Nichols M, et al. A novel cationic lipid greatly enhances plasmid DNA delivery and expression in mouse lung. Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11454–11459. [PubMed]
  • Ledley FD. Nonviral gene therapy: the promise of genes as pharmaceutical products. Hum Gene Ther. 1995 Sep;6(9):1129–1144. [PubMed]
  • Thierry AR, Lunardi-Iskandar Y, Bryant JL, Rabinovich P, Gallo RC, Mahan LC. Systemic gene therapy: biodistribution and long-term expression of a transgene in mice. Proc Natl Acad Sci U S A. 1995 Oct 10;92(21):9742–9746. [PubMed]
  • Song YK, Liu F, Chu S, Liu D. Characterization of cationic liposome-mediated gene transfer in vivo by intravenous administration. Hum Gene Ther. 1997 Sep 1;8(13):1585–1594. [PubMed]
  • Goddard CA, Ratcliff R, Anderson JR, Glenn E, Brown S, Gill DR, Hyde SC, MacVinish LJ, Huang L, Higgins CF, et al. A second dose of a CFTR cDNA-liposome complex is as effective as the first dose in restoring cAMP-dependent chloride secretion to null CF mice trachea. Gene Ther. 1997 Nov;4(11):1231–1236. [PubMed]
  • Rosenthal W, Seibold A, Antaramian A, Lonergan M, Arthus MF, Hendy GN, Birnbaumer M, Bichet DG. Molecular identification of the gene responsible for congenital nephrogenic diabetes insipidus. Nature. 1992 Sep 17;359(6392):233–235. [PubMed]
  • van Lieburg AF, Verdijk MA, Knoers VV, van Essen AJ, Proesmans W, Mallmann R, Monnens LA, van Oost BA, van Os CH, Deen PM. Patients with autosomal nephrogenic diabetes insipidus homozygous for mutations in the aquaporin 2 water-channel gene. Am J Hum Genet. 1994 Oct;55(4):648–652. [PubMed]
  • Simon DB, Karet FE, Rodriguez-Soriano J, Hamdan JH, DiPietro A, Trachtman H, Sanjad SA, Lifton RP. Genetic heterogeneity of Bartter's syndrome revealed by mutations in the K+ channel, ROMK. Nat Genet. 1996 Oct;14(2):152–156. [PubMed]
  • Simon DB, Nelson-Williams C, Bia MJ, Ellison D, Karet FE, Molina AM, Vaara I, Iwata F, Cushner HM, Koolen M, et al. Gitelman's variant of Bartter's syndrome, inherited hypokalaemic alkalosis, is caused by mutations in the thiazide-sensitive Na-Cl cotransporter. Nat Genet. 1996 Jan;12(1):24–30. [PubMed]

Articles from The Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation